Search results
To Your Good Health: The cause behind a case of CMML seems to be unknown
The Marshall News Messenger· 3 hours agoAccording to his death certificate, he died of lung cancer (not a surprise) and chronic...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoModerna will rival Pfizer and GSK, which launched their shots last year. Also, in June, Moderna and...
NHS genomics testing will be vital in supporting personalised cancer trials
Clinical Trials Arena via Yahoo Finance· 8 hours agoThe second trial, which has been recently launched by the NHS in collaboration with BioNTech, is...
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Motley Fool via Yahoo Finance· 4 days agoAnd therein lies the exciting new data. In case you aren't familiar, the most widely used...
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Zacks via Yahoo Finance· 2 days agoSummit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental...
Moderna Falls, Though Says Covid/Flu Shot Topped Rivals
Investor's Business Daily· 4 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
3 Reasons to Buy Moderna Stock
Motley Fool via Yahoo Finance· 6 days agoMerck is one of the leading oncology-focused drugmakers in the world, largely thanks to Keytruda, a medicine that has earned dozens of approvals for...
Is Merck & Co. Inc. (NYSE:MRK) The Best Healthcare Stock to Buy in 2024?
Insider Monkey via Yahoo Finance· 1 day agoWe recently published a list entitled Billionaire Israel Englander’s Top 10 Stock Picks for 2024....
Why Moderna Stock Is a No-Brainer Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoIn 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only...
Innovent braves bruising cytokine space, linking fusion protein to tumor responses in small study
FierceBiotech· 3 hours agoInnovent Biologics' bispecific immuno-oncology candidate IBI363 has been linked to a 100% response rate in a small cohort of Chinese lung cancer patients. IBI363 is a bispecific antibody fusion ...